MedTrace Logo

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

NCT06708299 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-13

No results posted yet for this study

Summary

Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.

Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.

The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.

Conditions

  • Recurrent Pericarditis

Interventions

DRUG

CardiolRx

The intervention will be administered orally (via syringe) with food twice daily.

Sponsors & Collaborators

  • Cardiol Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Paul Cremer, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-09-21
Completion
2026-10-21
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Greece
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06708299 on ClinicalTrials.gov